A framework for the development of effective anti-metastatic agents

Anderson, R. L. et al. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16(3), pp. 185-204. (doi: 10.1038/s41571-018-0134-8) (PMID:30514977) (PMCID:PMC7136167)

[img]
Preview
Text
171407.pdf - Published Version
Available under License Creative Commons Attribution.

1MB
[img]
Preview
Text
171407Suppl.pdf - Supplemental Material

165kB

Abstract

Most cancer-related deaths are a result of metastasis, and thus the importance of this process as a target of therapy cannot be understated. By asking ‘how can we effectively treat cancer?’, we do not capture the complexity of a disease encompassing >200 different cancer types — many consisting of multiple subtypes — with considerable intratumoural heterogeneity, which can result in variable responses to a specific therapy. Moreover, we have much less information on the pathophysiological characteristics of metastases than is available for the primary tumour. Most disseminated tumour cells that arrive in distant tissues, surrounded by unfamiliar cells and a foreign microenvironment, are likely to die; however, those that survive can generate metastatic tumours with a markedly different biology from that of the primary tumour. To treat metastasis effectively, we must inhibit fundamental metastatic processes and develop specific preclinical and clinical strategies that do not rely on primary tumour responses. To address this crucial issue, Cancer Research UK and Cancer Therapeutics CRC Australia formed a Metastasis Working Group with representatives from not-for-profit, academic, government, industry and regulatory bodies in order to develop recommendations on how to tackle the challenges associated with treating (micro)metastatic disease. Herein, we describe the challenges identified as well as the proposed approaches for discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert and Evans, Professor Jeff
Authors: Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., Marshall, J. F., Panico, M. B., Shaw, J. A., Steeg, P. S., Sullivan, M., Tong, W., Westwell, A. D., and Ritchie, J. W.A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Nature Reviews Clinical Oncology
Publisher:Nature Research
ISSN:1759-4774
ISSN (Online):1759-4782
Published Online:04 December 2018
Copyright Holders:Copyright © 2018 Springer Nature
First Published:First published in Nature Reviews Clinical Oncology 16(3): 185-204
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record